0001140361-18-022477.txt : 20180509 0001140361-18-022477.hdr.sgml : 20180509 20180509160122 ACCESSION NUMBER: 0001140361-18-022477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180507 FILED AS OF DATE: 20180509 DATE AS OF CHANGE: 20180509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novartis Bioventures Ltd CENTRAL INDEX KEY: 0001297709 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 18818179 BUSINESS ADDRESS: STREET 1: C/O NOVARTIS INTERNATIONAL AG STREET 2: WSJ-200.220 CITY: CH-4002 BASEL STATE: V8 ZIP: 0000000000 BUSINESS PHONE: 41-61-324-6210 MAIL ADDRESS: STREET 1: C/O NOVARTIS INTERNATIONAL AG STREET 2: WSJ-200.220 CITY: CH-4002 BASEL STATE: V8 ZIP: 0000000000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NOVARTIS AG CENTRAL INDEX KEY: 0001114448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 18818178 BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 BUSINESS PHONE: 01141613241111 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aeglea BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 901 S. MOPAC EXPRESSWAY, STE. 250 STREET 2: BARTON OAKS PLAZA ONE CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: (512) 942-2935 MAIL ADDRESS: STREET 1: 901 S. MOPAC EXPRESSWAY, STE. 250 STREET 2: BARTON OAKS PLAZA ONE CITY: AUSTIN STATE: TX ZIP: 78746 4 1 form4.xml FORM 4 X0306 4 2018-05-07 0001636282 Aeglea BioTherapeutics, Inc. AGLE 0001297709 Novartis Bioventures Ltd C/O NOVARTIS INTERNATIONAL AG LICHTSTRASSE 35 BASEL V8 CH-4056 SWITZERLAND true 0001114448 NOVARTIS AG C/O NOVARTIS INTERNATIONAL AG LICHTSTRASSE 35 BASEL V8 CH 4056 SWITZERLAND true Common Stock 2018-05-07 4 S 0 15548 10.11 D 2295376 D Common Stock 2018-05-08 4 S 0 26557 10.03 D 2268819 D Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.12. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. /s/ Bart Dzikowski, Authorized Signatory on behalf of Novartis Bioventures Ltd 2018-05-09 /s/ Stephan Sandmeier, Authorized Signatory on behalf of Novartis Bioventures Ltd 2018-05-09 /s/ Bart Dzikowski, Authorized Signatory on behalf of Novartis AG 2018-05-09 /s/ Stephan Sandmeier, Authorized Signatory on behalf of Novartis AG 2018-05-09 EX-24 2 ex24.htm EXHIBIT 24 - POWER OF ATTORNEY
Exhibit 24

POWER OF ATTORNEY

We, the undersigned, under the authority granted to each of us to sign jointly on behalf of Novartis AG, hereby grant powers to Anja Koenig, Stephan Sandmeier, Bartosz Dzikowski, Florian Muellershausen, Beat Steffen, Marc Ceulemans and Florent Gros and constitute and appoint any two of them jointly as our true and lawful attorneys and representatives and to act on our behalf and to sign filings to be made with the U.S. Securities and Exchange Commission (the “SEC”) relating to the shares of Aeglea BioTherapeutics, Inc. held by Novartis Bioventures, Ltd, an indirect subsidiary of Novartis AG, as required by the SEC (the “SEC Filings”), and to undertake and carry out all tasks and formalities on our behalf which may be required in connection with giving effect to the SEC Filings.

We, the undersigned, undertake to ratify and confirm whatever our true and lawful attorneys do or purport to do in good faith in the exercise of any power conferred by this Power of Attorney.

We, the undersigned, declare that a person who deals with our true and lawful attorneys in good faith may accept a written statement signed by such attorneys to the effect that this Power of Attorney has not been revoked as conclusive evidence of that fact.

The authority granted by this Power of Attorney shall expire immediately after the SEC Filings are no longer required.

IN WITNESS WHEREOF, this Power of Attorney is duly signed on this 8th day of May 2018.

 
Novartis AG
   
 
By: /s/ Christian Rehm
 
Name: Christian Rehm
 
Title: Authorized Signatory
   
 
By: /s/ Katja Roth Pellanda
 
Name: Katja Roth Pellanda
 
Title: Authorized Signatory